Clin2
NCT06612645Possibly a fitRecruiting

CAR T cell therapy for children with solid tumors that returned

Pediatric CancersSolid Tumor Pediatric

Part of Cancer clinical trials.

This trial tests a new type of immune therapy called CAR T cells designed to find and attack a protein called B7-H3 on solid tumor cells. It's for children and young adults whose cancer came back or didn't respond to standard treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
9 people
Ages
1 year to 25 years
Study type
Interventional

Who can take part

  • Your tumor must have a specific protein called B7-H3, which is checked from a past sample
  • Your cancer has returned after standard treatment or didn't respond well enough
  • You are between 1 and 25 years old
  • You are well enough to do daily activities (score of 50 or more on a standard scale)
  • Your heart, liver, and kidney functions are within safe limits, and oxygen levels are normal
  • You have not had certain cancer treatments for a specific time before starting trial procedures

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07078929Recruiting· Phase 1
CAR T-cell therapy for children with relapsed or refractory ALL

This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.

Bangkok, Bangkoknoi
NCT04897321Recruiting· Phase 1
CAR T therapy for children with B7-H3 solid tumors

This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.

Memphis, Tennessee
NCT07148050Recruiting· Phase 1
CAR T-cell therapy for children with solid tumors

This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.

Seattle, Washington
NCT07358260Not yet recruiting· Phase 1
B7-H3 CAR T cells for solid tumors in children and young adults

This trial tests a new type of immune cell therapy called CAR T cells that target a protein called B7-H3 found on many solid tumors. It is for children and young adults whose cancer has come back or stopped responding to standard treatments.

Boston, Massachusetts
NCT07172958Recruiting· Phase 1
Immune cell therapy for children with certain solid tumors

This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.

Washington D.C., District of Columbia
NCT06355739Recruiting
CAR T cells for children with relapsed B-cell leukemia

This trial tests whether giving you a special kind of immune cell, called a CAR T cell, can help fight your B-cell leukemia or lymphoma that has come back or not gone away with standard treatments. The cells are made from your own blood and designed to attack the cancer cells that carry a marker called CD19.

Tianjin, Tianjin Municipality

Hear when a new Pediatric Cancers trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.